A court finding that Yutrepia infringed two valid claims of United Therapeutics’ ‘327 patent has put the drug’s PH-ILD indication and broader availability at risk. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of Liquidia investors who lost money.
NEW YORK, Oct. 6, 2026 /PRNewswire/ — Yutrepia’s PH-ILD indication now faces possible removal after a court found two claims of United Therapeutics’ ‘327 patent valid and infringed. The ruling sent Liquidia Corporation (NASDAQ: LQDA) shares down roughly 57%. If you bought Liquidia stock and your position fell on this ruling, you may have legal rights. Investors who suffered losses are encouraged to see if they can recover their Liquidia losses now. You may also contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888) SueWallSt.
The finding covers two of the six claims United Therapeutics asserted against Yutrepia. Potential remedies include removal of the PH-ILD indication and broader restrictions on product availability. United Therapeutics has also sought an injunction. Chief Executive Officer Roger Jeffs said Liquidia disagrees with the decision and will pursue appellate options.
Yutrepia became eligible for final FDA approval when gating regulatory exclusivity expired on May 23, 2025, and the drug is sold for both PAH and PH-ILD. Liquidia reported Yutrepia sales of $300.3 million for the first six months of 2026, including approximately $129.9 million in the first quarter. Its second-quarter Form 10-Q also listed approximately $69.1 million in non-cancelable manufacturing and supply commitments. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of affected Liquidia investors.
Liquidia shareholders who lost money are urged to request a review of their LQDA losses or call (888) SueWallSt.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the LQDA Investigation
Q: Who is eligible to participate in the LQDA investigation?A: Investors who purchased LQDA stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.
Q: How much did LQDA stock drop?A: Shares fell approximately 57%. The decline followed a court finding that two of the six asserted claims of United Therapeutics’ ‘327 patent were valid and infringed by Yutrepia. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek recovery.
Q: What do LQDA investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate?A: You need brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any later sale dates and prices.
Q: What if I already sold my LQDA shares — can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought LQDA and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis. Any attorneys’ fees and expenses are subject to court approval.
Q: Do I need to go to court or give testimony?A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lqda-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-liquidia-corporation-302900091.html
SOURCE SueWallSt.com
